New pill targets Hard-to-Treat cancers with RAS gene flaw
NCT ID NCT07252479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental pill, AN9025, in adults with advanced solid tumors that have a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 118 participants will take the drug daily or weekly and be closely monitored for several months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS MUTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffit Cancer Center and Research Institute Hospital, Inc.
NOT_YET_RECRUITINGTampa, Florida, 33612-9497, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart RAS-Mutant cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?
- Smart drug targets two cancer weaknesses at once
- New drug combo targets Hard-to-Treat cancers with RAS mutations
- New pill targets Hard-to-Treat cancers in early human trial
- New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers